306 related articles for article (PubMed ID: 28719461)
21. DAXX, ATRX, and MSI in PanNET and Their Metastases: Correlation with Histopathological Data and Prognosis.
Gisder DM; Overheu O; Keller J; Nöpel-Dünnebacke S; Uhl W; Reinacher-Schick A; Tannapfel A; Tischoff I
Pathobiology; 2023; 90(2):71-80. PubMed ID: 35691289
[TBL] [Abstract][Full Text] [Related]
22. Hypo-methylation mediates chromosomal instability in pancreatic NET.
Marinoni I; Wiederkeher A; Wiedmer T; Pantasis S; Di Domenico A; Frank R; Vassella E; Schmitt A; Perren A
Endocr Relat Cancer; 2017 Mar; 24(3):137-146. PubMed ID: 28115389
[TBL] [Abstract][Full Text] [Related]
23. Differential diagnosis of sellar masses.
Freda PU; Post KD
Endocrinol Metab Clin North Am; 1999 Mar; 28(1):81-117, vi. PubMed ID: 10207686
[TBL] [Abstract][Full Text] [Related]
24. Liver metastases from pituitary carcinomas mimicking visceral well-differentiated neuroendocrine tumors: a series of four cases.
Venable ER; Kerr SE; Lopes MBS; Jones KA; Bellizzi AM; Mounajjed T; Raghunathan A; Hamidi O; Halfdanarson TR; Ryder M; Graham RP
Diagn Pathol; 2020 Jul; 15(1):81. PubMed ID: 32622369
[TBL] [Abstract][Full Text] [Related]
25. Context matters - Daxx and Atrx are not robust tumor suppressors in the murine endocrine pancreas.
Sun C; Estrella JS; Whitley EM; Chau GP; Lozano G; Wasylishen AR
Dis Model Mech; 2022 Aug; 15(8):. PubMed ID: 35976056
[TBL] [Abstract][Full Text] [Related]
26. Alternative lengthening of telomeres phenotype in malignant vascular tumors is highly associated with loss of ATRX expression and is frequently observed in hepatic angiosarcomas.
Liau JY; Tsai JH; Yang CY; Lee JC; Liang CW; Hsu HH; Jeng YM
Hum Pathol; 2015 Sep; 46(9):1360-6. PubMed ID: 26190196
[TBL] [Abstract][Full Text] [Related]
27. The diagnostic and prognostic utility of incorporating DAXX, ATRX, and alternative lengthening of telomeres to the evaluation of pancreatic neuroendocrine tumors.
Heaphy CM; Singhi AD
Hum Pathol; 2022 Nov; 129():11-20. PubMed ID: 35872157
[TBL] [Abstract][Full Text] [Related]
28. The differential diagnosis of lesions involving the sella turcica.
Kovacs K; Horvath E
Endocr Pathol; 2001; 12(4):389-95. PubMed ID: 11914472
[TBL] [Abstract][Full Text] [Related]
29. Clinical features of ATRX or DAXX mutated neuroblastoma.
Kurihara S; Hiyama E; Onitake Y; Yamaoka E; Hiyama K
J Pediatr Surg; 2014 Dec; 49(12):1835-8. PubMed ID: 25487495
[TBL] [Abstract][Full Text] [Related]
30. Leiomyosarcoma with alternative lengthening of telomeres is associated with aggressive histologic features, loss of ATRX expression, and poor clinical outcome.
Liau JY; Tsai JH; Jeng YM; Lee JC; Hsu HH; Yang CY
Am J Surg Pathol; 2015 Feb; 39(2):236-44. PubMed ID: 25229770
[TBL] [Abstract][Full Text] [Related]
31. KRAS and DAXX/ATRX gene mutations are correlated with the clinicopathological features, advanced diseases, and poor prognosis in Chinese patients with pancreatic neuroendocrine tumors.
Yuan F; Shi M; Ji J; Shi H; Zhou C; Yu Y; Liu B; Zhu Z; Zhang J
Int J Biol Sci; 2014; 10(9):957-65. PubMed ID: 25210493
[TBL] [Abstract][Full Text] [Related]
32. Pituitary chondrosarcoma: an unusual cause of a sellar mass presenting as a pituitary adenoma.
Allan CA; Kaltsas G; Evanson J; Geddes J; Lowe DG; Plowman PN; Grossman AB
J Clin Endocrinol Metab; 2001 Jan; 86(1):386-91. PubMed ID: 11232029
[TBL] [Abstract][Full Text] [Related]
33. Somatostatin receptor activity assessed by
Mapelli P; Bezzi C; Muffatti F; Ghezzo S; Baldassi F; Schiavo Lena M; Andreasi V; Canevari C; Magnani P; De Cobelli F; Gianolli L; Partelli S; Falconi M; Picchio M
Eur J Nucl Med Mol Imaging; 2023 Jul; 50(9):2818-2829. PubMed ID: 37010579
[TBL] [Abstract][Full Text] [Related]
34. Intrasellar chordomas mimicking pituitary adenoma.
Thodou E; Kontogeorgos G; Scheithauer BW; Lekka I; Tzanis S; Mariatos P; Laws ER
J Neurosurg; 2000 Jun; 92(6):976-82. PubMed ID: 10839258
[TBL] [Abstract][Full Text] [Related]
35. Rare sellar region tumors.
Halbauer DJ; Mészáros I; Dóczi T; Kajtár P; Pajor L; Kovács K; Gömöri E
Pathol Oncol Res; 2003; 9(2):134-7. PubMed ID: 12858221
[TBL] [Abstract][Full Text] [Related]
36. A comparison between the diagnostic value of gonadotropins, alpha-subunit, and chromogranin-A and their response to thyrotropin-releasing hormone in clinically nonfunctioning, alpha-subunit-secreting, and gonadotroph pituitary adenomas.
Nobels FR; Kwekkeboom DJ; Coopmans W; Hoekstra R; De Herder WW; Bouillon R; Lamberts SW
J Clin Endocrinol Metab; 1993 Sep; 77(3):784-9. PubMed ID: 7690365
[TBL] [Abstract][Full Text] [Related]
37. Two Extraordinary Sellar Neuronal Tumors: Literature Review and Comparison of Clinicopathologic Features.
Tan CL; Pang YH; Lim KHC; Sein L; Codd PJ; McLendon RE
Am J Clin Pathol; 2019 Feb; 151(3):241-254. PubMed ID: 30551183
[TBL] [Abstract][Full Text] [Related]
38. The genetics of neuroendocrine tumors.
Öberg K
Semin Oncol; 2013 Feb; 40(1):37-44. PubMed ID: 23391111
[TBL] [Abstract][Full Text] [Related]
39. ATRX represses alternative lengthening of telomeres.
Napier CE; Huschtscha LI; Harvey A; Bower K; Noble JR; Hendrickson EA; Reddel RR
Oncotarget; 2015 Jun; 6(18):16543-58. PubMed ID: 26001292
[TBL] [Abstract][Full Text] [Related]
40. [Analysis of MRI for tumor of the sellar region].
Jiang X; Yang W
Yan Ke Xue Bao; 2001 Dec; 17(4):224-8. PubMed ID: 12567510
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
